ND indicates not done.

T cells from CLL patients were expanded using autologous, native, unpulsed CLL cells as APCs. IFN-γ—ELISPOT assays were performed on days 14 or 21 with T2 cells as APCs. The T2 cells were pulsed with HLA-A0201 binding fibromodulin-derived peptides (F1-F4) or with a CLL unrelated control peptide derived from MAGE-3. HLA-A0201 restriction of the T cells was shown by adding an anti-MHC class 1 mAb (W6/32). Coincubation of T2 cells with DMSO and the patients' T cells served as negative controls, and the number of spots detected were subtracted from the experimental values. Given are the numbers of fibromodulin-specific spots per 100 000 T cells.